Defeat Duchenne Canada Launches 2025 Research Grant Cycle, Set to Commit its $20 Millionth Dollar to Groundbreaking Research

Dyne Therapeutics: The clinical impact of the FORCE™ platform

Duchenne muscular dystrophy (DMD) – An update on the DELIVER trial of DYNE-251 in males with DMD mutations amenable to exon 51 skipping. WATCH HEREThe post Dyne Therapeutics: The clinical impact of the FORCE™ platform appeared first on CureDuchenne.

Updates and Emerging Questions in Duchenne Muscular Dystrophy

Activity Overview: This webinar featuring Leslie Hayes, MD, of Boston Children’s Hospital and Harvard Medical School, and Stephen Chrzanowski, MD, of University of Massachusetts Chan Medical School, will discuss newborn screening and early intervention, gene therapy approvals and considerations, and enrolling study opportunities. Activity Type: On-Demand WebinarRelease Date: Sunday, March 30, 2025Expiration Date: Thursday, March 26, 2026Learning…

A crash course in understanding muscular dystrophy

A crash course in understanding muscular dystrophy asanovo 31 March 2025 10:00 11:00 Francesco Saverio Tedesco Job title: Senior Group Leader Lab: Stem Cells and Neuromuscular Regeneration LaboratoryLead, Team member Our next lecture in the series is with Francesco Saverio Tedesco, group leader for the Stem Cells and Neuromuscular Regeneration Laboratory. Neuromuscular and musculoskeletal disorders are a major cause of disability worldwide. A…